Zolpidem for insomnia

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 6, 2012, Pages 879-893

  Greenblatt, David J ^a   Roth, Thomas ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

Benzodiazepines; Hypnotics; Insomnia; Sleep; Zolpidem

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; BENZODIAZEPINE RECEPTOR; CARBAMAZEPINE; CIMETIDINE; CIPROFLOXACIN; CLARITHROMYCIN; EDULAR; ESZOPICLONE; FLUCONAZOLE; FLUOXETINE; FLUVOXAMINE; INTERMEZZO; ITRACONAZOLE; KETOCONAZOLE; MIDAZOLAM; ORAL CONTRACEPTIVE AGENT; RANITIDINE; RIFAMPICIN; RITONAVIR; TRIAZOLAM; UNCLASSIFIED DRUG; VORICONAZOLE; ZALEPLON; ZOLPIDEM; ZOLPIDEM TARTRATE; ZOPICLONE;

AGING; AMNESIA; AREA UNDER THE CURVE; AROUSAL; ATAXIA; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; ETHNICITY; EVIDENCE BASED MEDICINE; HIP FRACTURE; HUMAN; HYPERICUM PERFORATUM; HYPNOSIS; INSOMNIA; NONHUMAN; PHARMACODYNAMICS; PHYSICAL PERFORMANCE; REACTION TIME; REBOUND; REVIEW; SEX DIFFERENCE; SIDE EFFECT; SLEEP; TRAFFIC ACCIDENT;

ANIMALS; HUMANS; HYPNOTICS AND SEDATIVES; PYRIDINES; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 84858827822     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.667074     Document Type: Review

References (155)

1. Langtry HD, Benfield P. Zolpidem: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1990;40:291-313
2. Hoehns JD, Perry PJ. Zolpidem: A nonbenzodiazepine hypnotic for treatment of insomnia. Clin Pharm 1993;12:814-28
3. Roth T, Puech AJ, Paiva T. Zolpidem-place in therapy. In: Freeman H, Puech AJ, Roth T, editors. Zolpidem: An Update of its Pharmacological Properties and Thereapeutic Place in the Management of Insomnia. Elsevier; Paris: 1996. p. 215-30
4. Holm KJ, Goa KL. Zolpidem: An update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 2000;59:865-89
5. Harrison TS, Keating GM. Zolpidem: A review of its use in the management of insomnia. CNS Drugs 2005;19:65-89
6. Greenblatt DJ. Pharmacokinetic determinants of the clinical effects of benzodiazepine agonist hypnotics. In: Monti JM, Pandi-Perumal S, Mohler H, editors. GABA and Sleep. Springer; Basel: 2010. p. 95-118
7. Greenblatt DJ. Sleep and geriatric psychopharmacology. In: Pandi-Perumal SR, Verster JC, Monti JM, Lader MH, Langer SZ, editors. Sleep Disorders: Diagnosis and Therapeutics. Informa Healthcare; London: 2008. p. 163-73
8. Greenblatt DJ, Harmatz JS, Shader RI. Psychotropic drug prescribing in the United States: Extent, costs, and expenditures. J Clin Psychopharmacol 2011;31:1-3
9. Sieghart W. Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes. Pharmacol Rev 1995;47:181-234
10. Sanger DJ. The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents. CNS Drugs 2004;18(Suppl 1):9-15
11. Crestani F, Martin JR, Mohler H, et al. Mechanism of action of the hypnotic zolpidem in vivo. Br J Pharmacol 2000;131:1251-4
12. Patat A, Naef MM, Van Gessel E, et al. Flumazenil antagonizes the central effects of zolpidem, an imidazopyridine hypnotic. Clin Pharmacol Ther 1994;56:430-6
13. Byrnes JJ, Greenblatt DJ, Miller LG. Benzodiazepine receptor binding of non-benzodiazepines in vivo: Alpidem, zolpidem, and zopiclone. Brain Res Bull 1992;29:905-8
14. Sanger DJ, Benavides J, Perrault G, et al. Recent developments in the behavioral pharmacology of benzodiazepine receptors: Evidence for the functional significance of receptor subtypes. Neurosci Biobehav Rev 1994;18:355-72
15. Griebel G, Perrault G, Letang V, et al. New evidence that the pharmacological effects of benzodiazepine receptor ligands can be associated with activities at different BZ (omega) receptor subtypes. Psychopharmacology (Berl) 1999;146:205-13
16. Rudolph U, Crestani F, Möhler H. GABAA receptor subtypes: Dissecting their pharmacological functions. Trends Pharmacol Sci 2001; 22:188-94
17. Sanna E, Busonero F, Talani G, et al. Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA(A) receptor subtypes. Eur J Pharmacol 2002;451:103-10
18. Olsen RW, Sieghart W. GABAA receptors: Subtypes provide diversity of function and pharmacology. Neuropharmacology 2009;56:141-8 Important contemporary review of BZ receptor pharmacology
19. Rudolph U, Knoflach F. Beyond classical benzodiazepines: Novel therapeutic potential of GABAA receptor subtypes. Nat Rev Drug Discov 2011;10:685-97 Important contemporary review of BZ receptor pharmacology
20. Nutt DJ, Stahl SM. Searching for perfect sleep: The continuing evolution of GABAA receptor modulators as hypnotics. J Psychopharmacol 2009;24:1601-12 Important summary integrating basic and clinical pharmacology
21. Rush CR. Behavioral pharmacology of zolpidem relative to benzodiazepines: A review. Pharmacol Biochem Behav 1998;61:253-69
22. Lobo BL, Greene WL. Zolpidem: Distinct from triazolam? Ann Pharmacother 1997;31:625-32
23. von Moltke LL, Greenblatt DJ, Granda BW, et al. Zolpidem metabolism in vitro: Responsible cytochromes, chemical inhibitors, and in vivo correlations. Br J Clin Pharmacol 1999;48:89-97
24. Durand A, Thénot JP, Bianchetti G, et al. Comparative pharmacokinetic profile of two imidazopyridine drugs: Zolpidem and alpidem. Drug Metab Rev 1992;24:239-166
25. Patat A, Trocherie S, Thebault JJ, et al. EEG profile of intravenous zolpidem in healthy volunteers. Psychopharmacology (Berl) 1994;114:138-46
26. Salvá P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem: Therapeutic implications. Clin Pharmacokinet 1995;29:142-53
27. de Haas SL, Schoemaker RC, van Gerven JM, et al. Pharmacokinetics, pharmacodynamics and the pharmacokinetic/pharmacodynamic relationship of zolpidem in healthy subjects. J Psychopharmacol 2010;24:1619-29
28. Drover DR. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: Zaleplon, zolpidem and zopiclone. Clin Pharmacokinet 2004;43:227-38
29. Friedman H, Greenblatt DJ, Burstein ES, et al. Population study of triazolam pharmacokinetics. Br J Clin Pharmacol 1986;22:639-42
30. Greenblatt DJ, Harmatz JS, Friedman H, et al. A large-sample study of diazepam pharmacokinetics. Ther Drug Monit 1989;11:652-7
31. Olubodun JO, Ochs HR, von Moltke LL, et al. Pharmacokinetic properties of zolpidem in elderly and young adults: Possible modulation by testosterone in men. Br J Clin Pharmacol 2003;56:297-304
32. Greenblatt DJ, Harmatz JS, von Moltke LL, et al. Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: Evaluation of sex-dependent differences. J Pharmacol Exp Ther 2000;293:435-43
33. Greenblatt DJ, von Moltke LL. Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs. J Clin Pharmacol 2008;48:1350-5
34. Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 2005;44:33-60
35. Schwartz JB. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther 2007;82:87-96
36. McLean A, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004;56:163-84
37. Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly: Therapeutic considerations. Clin Pharmacokinet 1991;21:165-77; 262-273
38. Greenblatt DJ. Preparation of scientific reports on pharmacokinetic drug interaction studies. J Clin Psychopharmacol 2008;28:369-73
39. Greenblatt DJ, von Moltke LL. Clinical studies of drug-drug interactions: Design and interpretation. In: Pang KS, Rodrigues AD, Peter RM, editors. Enzyme and Transporter-Based Drug- Drug Interactions: Progress and Future Challenges. Springer; New York: 2010. p. 625-49
40. von Moltke LL, Greenblatt DJ. Clinical drug interactions due to metabolic inhibition: Prediction, assessment, and interpretation. In: Lu C, Li AP, editors. Enzyme Inhibition in Drug Discovery and Development. Hoboken NJ, John Wiley & Sons; 2010. p. 533-47
41. Greenblatt DJ. Introduction to drug-drug interactions. In: Piscitelli SC, Rodvold KA, Pai MP, editors. Drug Interactions in Infectious Diseases. 3rd edition. Human Press; New York: 2011. p. 1-10
42. Olubodun JO, Ochs HR, Trüten V, et al. Zolpidem pharmacokinetic properties in young females: Influence of smoking and oral contraceptive use. J Clin Pharmacol 2002;42:1142-6
43. Hesse LM, von Moltke LL, Greenblatt DJ. Clinically important drug interactions with zopiclone, zolpidem and zaleplon. CNS Drugs 2003;17:513-32
44. Vlase L, Popa A, Neag M, et al. Pharmacokinetic interaction between zolpidem and ciprofloxacin in healthy volunteers. Eur J Drug Metab Pharmacokinet 2011;35:83-7
45. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Differential impairment of triazolam and zolpidem clearance by ritonavir. J Acquir Immune Defic Syndr 2000;24:129-36
46. von Moltke LL, Weemhoff JL, Perloff MD, et al. Effect of zolpidem on human Cytochrome P450 activity, and on transport mediated by P-glycoprotein. Biopharm Drug Dispos 2002;23:361-7
47. Polasek TM, Sadagopal JS, Elliot DJ, et al. In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A. Eur J Clin Pharmacol 2010;66:275-83
48. Greenblatt DJ, Harmatz JS, von Moltke LL, et al. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Clin Pharmacol Ther 1998;64:553-61
49. Shader RI, Dreyfuss D, Gerrein JR, et al. Sedative effects and impaired learning and recall following single oral doses of lorazepam. Clin Pharmacol Ther 1986;39:526-9
50. Otmani S, Demazieres A, Staner C, et al. Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Hum Psychopharmacol 2008;23:693-705
51. Balkin TJ, O'Donnell VM, Wesensten N, et al. Comparison of the daytime sleep and performance effects of zolpidem versus triazolam. Psychopharmacology (Berl) 1992;107:83-8
52. Roehrs T, Merlotti L, Zorick F, et al. Sedative, memory, and performance effects of hypnotics. Psychopharmacology (Berl) 1994;116:130-4
53. Rush CR and Griffiths RR. Zolpidem, triazolam, and temazepam: Behavioral and subject-rated effects in normal volunteers. J Clin Psychopharmacol 1996;16:146-57
54. Rush CR, Armstrong DL, Ali JA, et al. Benzodiazepine-receptor ligands in humans: Acute performance-impairing, subject-rated and observer-rated effects. J Clin Psychopharmacol 1998;18:154-66
55. Mintzer MZ, Frey JM, Griffiths RR. Zolpidem is differentiated from triazolam in humans using a three-response drug discrimination procedure. Behav Pharmacol 1998;9:545-59
56. Troy SM, Lucki I, Unruh MA, et al. Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance. J Clin Psychopharmacol 2000;20:328-37
57. Priest R, Terzano M, Parrino L, et al. Efficacy of zolpidem in insomnia. Eur Psychiatry 1997;12(Suppl 1):5-14
58. Nowell PD, Mazumdar S, Buysse DJ, et al. Benzodiazepines and zolpidem for chronic insomnia: A meta-analysis of treatment efficacy. J Am Med Assoc 1997;278:2170-6. Comprehensive analysis of clinical trials involving zolpidem
59. Dündar Y, Dodd S, Strobl J, et al. Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: A systematic review and meta-analysis. Hum Psychopharmacol 2004;19:305-22. Comprehensive analysis of clinical trials involving zolpidem
60. Buscemi N, Vandermeer B, Friesen C, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: A meta-analysis of RCTs. J Gen Intern Med 2007;22:1335-50. Comprehensive analysis of clinical trials involving zolpidem
61. Glass J, Lanctot KL, Herrmann N, et al. Sedative hypnotics in older people with insomnia: Meta-analysis of risks and benefits. Br Med J 2005;331:1169. Comprehensive analysis of clinical trials involving zolpidem
62. Dolder C, Nelson M, McKinsey J. Use of non-benzodiazepine hypnotics in the elderly: Are all agents the same? CNS Drugs 2007;21:389-405
63. Krystal AD. A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: The empirical basis for U.S. clinical practice. Sleep Med Rev 2009;13:265-74
64. Roehrs TA, Randall S, Harris E, et al. Twelve months of nightly zolpidem does not lead to dose escalation: A prospective placebo-controlled study. Sleep 2011;34:207-12
65. Undén M, Roth-Schechter B. Next day effects after nighttime treatment with zolpidem: A review. Eur Psychiatry 1996;11(Suppl 1):21s-30s
66. Allain H, Monti J. General safety profile of zolpidem: Safety in elderly, overdose and rebound effects. Eur Psychiatry 1997;12(Suppl 1):21-9
67. Hajak G, Bandelow B. Safety and tolerance of zolpidem in the treatment of disturbed sleep: A post-marketing surveillance of 16944 cases. Int Clin Psychopharmacol 1998;13:157-67
68. Darcourt G, Pringuey D, Sallière D, et al. The safety and tolerability of zolpidem: An update. J Psychopharmacol 1999;13:81-93
69. Zammit G. Comparative tolerability of newer agents for insomnia. Drug Saf 2009;32:735-48
70. Monti JM, Attali P, Monti D, et al. Zolpidem and rebound insomnia-A double-blind, controlled polysomnographic study in chronic insomniac patients. Pharmacopsychiatry 1994;27:166-75
71. Ware JC, Walsh JK, Scharf MB, et al. Minimal rebound insomnia after treatment with 10-mg zolpidem. Clin Neuropharmacol 1997;20:116-25
72. Lahmeyer H, Wilcox CS, Kann J, et al. Subjective efficacy of zolpidem in outpatients with chronic insomnia: A double-blind comparison with placebo. Clin Drug Investig 1997;13:134-44
73. Roehrs TA, Randall S, Harris E, et al. Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: A prospective placebo-controlled study. J Psychopharmacol 2011; [Epub ahead of print]
74. Hajak G, Hedner J, Eglin M, et al. A 2-week efficacy and safety study of gaboxadol and zolpidem using electronic diaries in primary insomnia outpatients. Sleep Med 2009;10:705-12
75. Ator NA. Contributions of GABAA receptor subtype selectivity to abuse liability and dependence potential of pharmacological treatments for anxiety and sleep disorders. CNS Spectr 2005;10:31-9
76. Rowlett JK, Platt DM, Lelas S, et al. Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates. PNAS 2005;102:915-20
77. Follesa P, Mancuso L, Biggio F, et al. Changes in GABA(A) receptor gene expression induced by withdrawal of, but not by long-term exposure to, zaleplon or zolpidem. Neuropharmacology 2002;42:191-8
78. Evans SM, Funderburk FR, Griffiths RR. Zolpidem and triazolam in humans: Behavioral and subjective effects and abuse liability. J Pharmacol Exp Ther 1990;255:1246-54
79. Jaffe JH, Bloor R, Crome I, et al. A postmarketing study of relative abuse liability of hypnotic sedative drugs. Addiction 2004;99:165-73
80. Hajak G, Müller WE, Wittchen HU, et al. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: A review of case reports and epidemiological data. Addiction 2003;98:1371-8
81. Victorri-Vigneau C, Dailly E, Veyrac G, et al. Evidence of zolpidem abuse and dependence: Results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. Br J Clin Pharmacol 2007;64:198-209
82. Goldman SA. Limitations and strengths of spontaneous reports data. Clin Ther 1998;20(Suppl C):C40-4
83. Cumming RG. Epidemiology of medication-related falls and fractures in the elderly. Drugs Aging 1998;12:43-53
84. Tamblyn R, Abrahamowicz M, du Berger R, et al. A 5-year prospective assessment of the risk associated with individual benzodiazepines and doses in new elderly users. J Am Geriatr Soc 2005;53:233-41
85. Schneeweiss S, Wang PS. Claims data studies of sedative-hypnotics and hip fractures in older people: Exploring residual confounding using survey information. J Am Geriatr Soc 2005;53:948-54
86. Allain H, Bentue-Ferrer D, Polard E, et al. Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: A comparative review. Drugs Aging 2005;22:749-65
87. Vermeeren A. Residual effects of hypnotics: Epidemiology and clinical implications. CNS Drugs 2004;18:297-328
88. Frey DJ, Ortega JD, Wiseman C, et al. Influence of zolpidem and sleep inertia on balance and cognition during nighttime awakening: A randomized placebo-controlled trial. J Am Geriatr Soc 2011;59:73-81
89. Mets MA, Volkerts ER, Olivier B, et al. Effect of hypnotic drugs on body balance and standing steadiness. Sleep Med Rev 2010;14:259-67
90. Wang PS, Bohn RL, Glynn RJ, et al. Zolpidem use and hip fractures in older people. J Am Geriatr Soc 2001;49:1685-90
91. Zint K, Haefeli WE, Glynn RJ, et al. Impact of drug interactions, dosage, and duration of therapy on the risk of hip fracture associated with benzodiazepine use in older adults. Pharmacoepidemiol Drug Saf 2010;19:1248-55
92. Chang CM, Chen MJ, Tsai CY, et al. Medical conditions and medications as risk factors of falls in the inpatient older people: A case-control study. Int J Geriatr Psychiatry 2011;26:602-7
93. Finkle WD, Der JS, Greenland S, et al. Risk of fractures requiring hospitalization after an initial prescription for zolpidem, alprazolam, lorazepam, or diazepam in older adults. J Am Geriatr Soc 2011;59:1883-90
94. Rhalimi M, Helou R, Jaecker P. Medication use and increased risk of falls in hospitalized elderly patients: A retrospective, case-control study. Drugs Aging 2009;26:847-52
95. Avidan AY, Fries BE, James ML, et al. Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in Michigan nursing homes. J Am Geriatr Soc 2005;53:955-62
96. Dubois S, Bedard M, Weaver B. The impact of benzodiazepines on safe driving. Traffic Inj Prev 2008;9:404-13
97. Neutel I. Benzodiazepine-related traffic accidents in young and elderly drivers. Hum Psychopharmacol Clin Exp 1998;13:S115-23
98. Orriols L, Philip P, Moore N, et al. Benzodiazepine-like hypnotics and the associated risk of road traffic accidents. Clin Pharmacol Ther 2011;89:595-601
99. Smink BE, Lusthof KJ, de Gier JJ, et al. The relation between the blood benzodiazepine concentration and performance in suspected impaired drivers. J Forensic Leg Med 2008;15:483-8
100. Jones AW, Holmgren A, Kugelberg FC. Concentrations of scheduled prescription drugs in blood of impaired drivers: Considerations for interpreting the results. Ther Drug Monit 2007;29:248-60
101. Gustavsen I, Al-Sammurraie M, Morland J, et al. Impairment related to blood drug concentrations of zopiclone and zolpidem compared to alcohol in apprehended drivers. Accid Anal Prev 2009;41:462-6
102. Yang YH, Lai JN, Lee CH, et al. Increased risk of hospitalization related to motor vehicle accidents among people taking zolpidem: A case-crossover study. J Epidemiol 2011;21:37-43
103. Gustavsen I, Bramness JG, Skurtveit S, et al. Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam. Sleep Med 2008;9:818-22
104. Philip P, Sagaspe P, Taillard J, et al. Fatigue, sleepiness, and performance in simulated versus real driving conditions. Sleep 2005;28:1511-16 Highlights the important distinction between simulated and real driving
105. Philip P, Sagaspe P, Taillard J, et al. Fatigue, sleep restriction, and performance in automobile drivers: A controlled study in a natural environment. Sleep 2003;26:277-80
106. Pandi-Perumal SR, Verster JC, Kayumov L, et al. Sleep disorders, sleepiness and traffic safety: A public health menace. Braz J Med Biol Res 2006;39:863-71
107. Sagberg F. Road accidents caused by drivers falling asleep. Accid Anal Prev 1999;31:639-49
108. Powell NB, Schechtman KB, Riley RW, et al. The road to danger: The comparative risks of driving while sleepy. Laryngoscope 2001;111:887-93
109. Connor J, Norton R, Ameratunga S, et al. Driver sleepiness and risk of serious injury to car occupants: Population based case control study. Br Med J 2002;324:1125
110. Staner L, Ertle S, Boeijinga P, et al. Next-day residual effects of hypnotics in DSM-IV primary insomnia: A driving simulator study with simultaneous electroencephalogram monitoring. Psychopharmacology (Berl) 2005;181:790-8
111. Verster JC, Veldhuijzen DS, Volkerts ER. Residual effects of sleep medication on driving ability. Sleep Med Rev 2004;8:309-25
112. Verster JC, Veldhuijzen DS, Patat A, et al. Hypnotics and driving safety: Meta-analyses of randomized controlled trials applying the on-the-road driving test. Curr Drug Saf 2006;1:63-71
113. Verster JC, Roth T. Standard operation procedures for conducting the on-the-road driving test, and measurement of the standard deviation of lateral position (SDLP). Int J Gen Med 2011;4:359-71
114. Verster JC, Volkerts ER, Olivier B, et al. Zolpidem and traffic safety - the importance of treatment compliance. Curr Drug Saf 2007;2:220-6
115. Hoque R and Chesson AL. Zolpidem-induced sleepwalking, sleep related eating disorder, and sleep-driving: Fluorine-18-flourodeoxyglucose positron emission tomography analysis, and a literature review of other unexpected clinical effects of zolpidem. J Clin Sleep Med 2009;5:471-6
116. Pressman MR. Sleep driving: Sleepwalking variant or misuse of zdrugs? Sleep Med Rev 2011;15:285-92
117. Dolder CR, Nelson MH. Hypnosedative-induced complex behaviours: Incidence, mechanisms and management. CNS Drugs 2008;22:1021-36
118. Poceta JS. Zolpidem ingestion, automatisms, and sleep driving: A clinical and legal case series. J Clin Sleep Med 2011;7:632-8
119. Ben-Hamou M, Marshall NS, Grunstein RR, et al. Spontaneous adverse event reports associated with zolpidem in Australia 2001-2008. J Sleep Res 2011;20:559-68
120. Owen RT. Novel zolpidem formulations. Drugs Today (Barc) 2009;45:395-400
121. Barkin RL. Zolpidem extended-release: A single insomnia treatment option for sleep induction and sleep maintenance symptoms. Am J Ther 2007;14:299-305
122. Zammit G. Zolpidem extended-release: Therapy for sleep induction and sleep maintenance difficulties. Expert Opin Drug Metab Toxicol 2008;4:325-31
123. Greenblatt DJ, Legangneux E, Harmatz JS, et al. Dynamics and kinetics of a modified-release formulation of zolpidem: Comparison with immediate-release standard zolpidem and placebo. J Clin Pharmacol 2006;46:1469-80
124. Weinling E, McDougall S, Andre F, et al. Pharmacokinetic profile of a new modified release formulation of zolpidem designed to improve sleep maintenance. Fund Clin Pharmacol 2006;20:397-403
125. Roth T, Soubrane C, Titeux L, et al. Efficacy and safety of zolpidem-MR: A double-blind, placebo-controlled study in adults with primary insomnia. Sleep Med 2006;7:397-406
126. Krystal AD, Erman M, Zammit GK, et al. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: A 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep 2008; 31:79-90
127. Walsh JK, Soubrane C, Roth T. Efficacy and safety of zolpidem extended release in elderly primary insomnia patients. Am J Geriatr Psychiatry 2008;16:44-57
128. Fava M, Asnis GM, Shrivastava R, et al. Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder. J Clin Psychopharmacol 2009;29:222-30
129. Kleykamp BA, Griffiths RR, McCann UD, et al. Acute effects of zolpidem extended-release on cognitive performance and sleep in healthy males after repeated nightly use. Exp Clin Psychopharmacol 2011;20:28-39
130. Staner L, Eriksson M, Cornette F, et al. Sublingual zolpidem is more effective than oral zolpidem in initiating early onset of sleep in the post-nap model of transient insomnia: A polysomnographic study. Sleep Med 2009;10:616-20
131. Staner C, Joly F, Jacquot N, et al. Sublingual zolpidem in early onset of sleep compared to oral zolpidem: Polysomnographic study in patients with primary insomnia. Curr Med Res Opin 2010;26:1423-31
132. Staner L, Danjou P, Luthringer R. A new sublingual formulation of zolpidem for the treatment of sleep-onset insomnia. Expert Rev Neurother 2012;12:141-53
133. Lankford A. Sublingual zolpidem tartrate lozenge for the treatment of insomnia. Expert Rev Clin Pharmacol 2009;2:333-7
134. Roth T, Mayleben D, Corser BC, et al. Daytime pharmacodynamic and pharmacokinetic evaluation of low-dose sublingual transmucosal zolpidem hemitartrate. Hum Psychopharmacol 2008;23:13-20
135. Roth T, Hull SG, Lankford DA, et al. Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings. Sleep 2008;31:1277-84
136. Sateia MJ and Nowell PD. Insomnia. Lancet 2004;364:1959-73
137. Kupfer DJ, Reynolds CF. Management of insomnia. N Engl J Med 1997;336:341-6
138. Drake CL, Roehrs T, Roth T. Insomnia causes, consequences, and therapeutics: An overview. Depress Anxiety 2003;18:163-76
139. Simon GE, vonKorff M. Prevalence, burden, and treatment of insomnia in primary care. Am J Psychiatry 1997;154:1417-23
140. Thase ME. Correlates and consequences of chronic insomnia. Gen Hosp Psychiatry 2005;27:100-12
141. Metlaine A, Leger D, Choudat D. Socioeconomic impact of insomnia in working populations. Ind Health 2005;43:11-19
142. Kessler RC, Berglund PA, Coulouvrat C, et al. Insomnia and the performance of US workers: Results from the America insomnia survey. Sleep 2011;34:1161-71
143. Hulhoven R, Desager JP, Harvengt C, et al. Lack of interaction between zolpidem and H2 antagonists, cimetidine and ranitidine. Int J Clin Pharmacol Res 1988;8:471-6
144. Piergies AA, Sweet J, Johnson M, et al. The effect of co-administration of zolpidem with fluoxetine: Pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther 1996;34:178-83
145. Allard S, Sainati S, Roth-Schechter B, et al. Minimal interaction between fluoxetine and multiple-dose zolpidem in healthy women. Drug Metab Dispos 1998;26:617-22
146. Saari TI, Laine K, Leino K, et al. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects. Br J Clin Pharmacol 2007;63:116-20
147. Luurila H, Kivistö KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. Eur J Clin Pharmacol 1998;54:336-40
148. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. Clin Pharmacol Ther 1998;64:661-71
149. Vlase L, Popa A, Neag M, et al. Effect of fluvoxamine on the pharmacokinetics of zolpidem: A two-treatment period study in healthy volunteers. Clin Exp Pharmacol Physiol 2012;39:9-12
150. Farkas D, Volak LP, Harmatz JS, et al. Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem. Clin Pharmacol Ther 2009; 85:644-50
151. Cysneiros RM, Farkas D, Harmatz JS, et al. Pharmacokinetic and pharmacodynamic interactions between zolpidem and caffeine. Clin Pharmacol Ther 2007;82:54-62
152. Vlase L, Popa A, Neag M, et al. Pharmacokinetic interaction between zolpidem and carbamazepine in healthy volunteers. J Clin Pharmacol 2011;51:1233-6
153. Villikka K, Kivistö KT, Luurila H, et al. Rifampin reduces plasma concentrations and effects of zolpidem. Clin Pharmacol Ther 1997;62:629-34
154. Hojo Y, Echizenya M, Ohkubo T, et al. Drug interaction between St John's wort and zolpidem in healthy subjects. J Clin Pharm Ther 2011;36:711-15
155. Merlotti L, Roehrs T, Koshorek G, et al. The dose effects of zolpidem on the sleep of healthy normals. J Clin Psychopharmacol 1989;9:9-14